By 2030, it is anticipated that the Poland infectious disease therapeutics market will reach a value of $1012 Mn from $695 Mn in 2022, growing at a CAGR of 4.8% during 2022-2030. Infectious Disease Therapeutics in Poland is dominated by a few domestic pharmaceutical companies such as Polpharma Group, Selvita and Adamed Group. The Infectious Disease Therapeutics market in Poland is segmented into different therapeutic areas and different diseases type. The major factors affecting the Poland infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of Poland.
By 2030, it is anticipated that the Poland infectious disease therapeutics market will reach a value of $1012 Mn from $695 Mn in 2022, growing at a CAGR of 4.8% during 2022-2030.
Poland is a high-income, developed country in Central Europe bordered by Belarus, the Czech Republic, Germany, Lithuania, Russia, Slovakia, and Ukraine. Poland is prone to the infectious diseases listed below, according to the World Factbook. Major infectious diseases in Poland include tick-borne encephalitis, influenza, acute diarrhoea, scarlet fever, and viral hepatitis.
The government of Poland spends 6.5 % of its GDP on healthcare. International pharmaceutical corporations such as Gilead Sciences, GlaxoSmithKline, and AbbVie are among the market's key players. The National Institute of Public Health - the National Institute of Hygiene and the National Institute of Tuberculosis and Lung Diseases are two research institutions and hospitals in Poland that specialise in infectious disease research and treatment.
Market Growth Drivers Analysis
The government has established a number of programmes to enhance access to infectious disease treatments, including the National Program for the Prevention and Control of HIV/AIDS and Viral Hepatitis, which intends to give free treatment to patients suffering from these diseases. Poland has a diverse economy and is close to Western European markets (agriculture, a variety of industries, and services). These aspects could boost Poland's infectious disease therapeutics market.
Market Restraints
The Polish healthcare system is generally cost-conscious, and before reimbursing new pharmaceuticals, healthcare payers frequently request evidence of cost-effectiveness. Companies may find it challenging to get market access and achieve significant commercial growth as a result of this. Poland, in general, does not invest in R&D and has a large proportion of exports in imports. These factors may deter new entrants into the Poland infectious disease therapeutics market.
Key Players
July 2022: Polpharma has formed a partnership with Pikralida, a biopharmaceutical start-up developing a revolutionary therapeutic treatment to prevent the onset of epilepsy following a traumatic brain injury or stroke. The collaboration entails the development of a drug substance for the clinical candidate PKL-021, which is required to support the preclinical research programme, as well as the production of an investigational medicinal product for the phase one clinical trial. Polpharma will carry out the production process in compliance with Good Manufacturing Practice (GMP) standards.
February 2022: Immagene and Selvita have been working together on an innovative integrated drug development effort to improve the therapeutic benefit of immuno-oncology medicines over the past year. Immagene is guiding and utilising Selvita's substantial drug discovery capabilities in this continuing research. Selvita is in charge of a wide range of drug development operations, including medicinal chemistry, in vitro pharmacology, DMPK, and recombinant protein manufacturing. Immagene and Selvita's collaboration is now expanding.
In Poland, the regulation and reimbursement of infectious disease therapeutics are overseen by several entities, including the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL), the Ministry of Health, and the National Health Fund (NFZ).
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Poland infectious disease therapeutics market will reach a value of $1012 Mn from $695 Mn in 2022, growing at a CAGR of 4.8% during 2022-2030.
In Poland, the regulation and reimbursement of infectious disease therapeutics are overseen by several entities, including the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL), the Ministry of Health, and the National Health Fund (NFZ).
Infectious Disease Therapeutics in Poland is dominated by domestic pharmaceutical companies such as Polpharma Group, Selvita and Adamed Group.